Virus-like particle based vaccines for Alzheimer disease.
Vaccines targeting the amyloid-β (Aβ) peptide have promise as immunotherapies for the treatment of Alzheimer disease (AD). Human trials of a first generation Aβ vaccine highlighted the need for a vaccine strategy that could consistently induce high-titer antibodies against Aβ without also inducing inflammatory auto-reactive T-cell responses. in this review, I will describe the use of virus-like particle (vLP) based vaccines against Aβ that can potentially satisfy these demands. vLPs can serve as highly multivalent platforms for the display of diverse antigens on their surfaces. vLP display markedly increases the immunogenicity of antigens, including self-antigens. vLP- based immunogens targeting Ab have been developed by several different groups, and have demonstrated effectiveness in animal models of AD. One vLP-based candidate vaccine for AD, CAD106, developed by Cytos Biotechnology and Novartis Pharmaceuticals, is currently in human clinical trials.
Chackerian
Bryce
B
Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA. bchackerian@salud.unm.edu
D000544:Alzheimer Disease / Q000517:prevention & control*; D023582:Alzheimer Vaccines / Q000276:immunology*; D016229:Amyloid beta-Peptides / Q000276:immunology; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D022721:Vaccines, Virosome / Q000276:immunology
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D022721:Vaccines, Virosome